Bayer's recent drug launches and diverse operations support steady gains.
Bayer issued 2017 guidance and reported fourth-quarter results that were in line with both our and consensus expectations, and we don’t expect a material change to our fair value estimate. The investment community appears to be too concerned about the Monsanto acquisition and a relatively weak pipeline, but we continue to view the stock as undervalued. While the company’s moat is weighed down by the no-moat material science group, we still think the company’s narrow moat is secure, buoyed by the...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.